Program News
News and stories about members of the UNC Lineberger Molecular Therapeutics Research Program
-
‘If you’re trying to make a difference in cancer, you can’t go slow’
Chad Pecot, MD, leads cancer RNA research at UNC Lineberger, creating innovative therapies and promising treatment strategies for multiple cancer mutations.
-
UNC Lineberger faculty members presenting Het Talks during University Research Week
Three UNC Lineberger members will share their research during the Het Talks at UNC-Chapel Hill’s University Research Week, Oct. 20-24.
-
Researchers awarded $11.2M grant to close endometrial cancer survival gap
The National Cancer Institute has awarded a Cancer Health Disparities Specialized Program of Research Excellence (SPORE) in Endometrial Cancer grant to UNC Lineberger’s Victoria Bae-Jump, MD, PhD, and Hazel Nichols, PhD.
-
UNC Lineberger launches groundbreaking trial for rare, aggressive thyroid cancer
UNC Lineberger has launched a first-of-its-kind clinical trial aimed at improving outcomes in BRAF wildtype anaplastic thyroid cancer (ATC). Siddharth Sheth, DO, MPH, and Jeffrey Blumberg, MD, FACS, are leading the trial.
-
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes
Chad Pecot, MD, and colleagues have developed a “two-in-one” molecule that targets hard-to-treat cancers by silencing two key genes — KRAS and MYC — while also delivering drugs directly to affected tumors.
-
UNC honors three cancer center members with 2025 Hettleman Prizes
Sarah Cohen, PhD, Marissa Hall, PhD, and Lindsey James, PhD, were awarded Hettleman Prizes, which recognizes UNC-Chapel Hill early-career faculty who exemplify groundbreaking and innovative research.
-
Uniquely engineered KRAS-targeted cancer drug found to be effective in early studies
Chad Pecot, MD, and colleagues have demonstrated that a uniquely engineered drug that zeroes in on a mutated gene called KRAS G12V could potentially stop KRAS-dependent cancers in their tracks.
-
UNC Lineberger commemorates National Cancer Research Month
The American Association of Cancer Research has designated May as National Cancer Research Month to help underscore the importance and impact of cancer research.
-
New drug combinations found to potentially be more effective in targeting pancreatic cancers
UNC Lineberger researchers and colleagues have discovered an important overlap in genes regulated by the activity of three proteins that support the growth of pancreatic cancer.
-
UNC Lineberger and UNC faculty and trainees present findings at AACR annual meeting
Nearly 30 UNC Lineberger and UNC faculty and trainees will present findings and participate during the American Association for Cancer Research annual meeting in Chicago, April 25-30.
-
Fired up for RNA
Chad Pecot, MD, is revolutionizing RNA therapies for cancer through his company EnFuego Therapeutics and the new UNC RNA Discovery Center.
-
UNC Lineberger members recognized for highly cited research
Nine UNC Lineberger members wrote some of the most influential scientific papers in the past decade, according to an independent analysis of research publications.
-
UNC scientist’s work contributes to Nobel Prize in Chemistry
The 2024 Nobel Prize in Chemistry recognized groundbreaking work in computational protein design and protein structure prediction. Brian Kuhlman, PhD, made significant contributions to this work while a postdoctoral researcher in the Baker lab.
-
A call to bridge the gap in cancer clinical trial funding
In a Journal of Clinical Oncology editorial, Yara Abdou, MD, and Norman E. Sharpless, MD, share their concerns about a growing reliance on industry-sponsored cancer clinical trials in the U.S.
-
Rushing receives $3.9 million NCI grant to create the Human Cancer Metabolome Atlas
Blake Rushing, PhD, will support the development of the Human Cancer Metabolome Atlas. The project aims to map the complex metabolic processes that drive cancer’s progression and resistance to treatment.